Female Chemist Pioneers Leukemia Drug, Changing Children’s Lives

In a groundbreaking achievement for cancer treatment, researchers at the Sloan Kettering Institute and Weill Cornell Medical College announced on December 6, 1954, the successful use of a new chemotherapeutic agent that sent children with acute leukemia into remission. This drug, known as 6-mercaptopurine (6-MP), marked a significant advancement in the fight against leukemia and laid the foundation for future drug design methodologies.

Gertrude Elion, a pioneering female chemist, played a crucial role in this discovery. After earning her master’s degree in chemistry in 1941, she faced significant barriers to her career due to gender biases that restricted women from many research positions. Consequently, she initially worked as a high school chemistry teacher and a food quality tester. In 1944, she secured a position in the lab of George Hitchings at Burroughs-Wellcome, where she began to focus on innovative drug development.

Elion and Hitchings approached the challenge of drug design by shifting away from traditional trial-and-error methods. They theorized that since all living cells require nucleic acids for growth, fast-replicating cells, such as cancerous and bacterial cells, would need more of these compounds. Consequently, they focused on developing drugs that could inhibit nucleic acid synthesis, effectively stunting cancer growth.

In 1950, their research led to the discovery of 6-MP, a compound derived from purine. Early tests showed that it could inhibit the growth of both bacterial and leukemia cells in laboratory settings. Over the next two years, they conducted animal trials, observing that 6-MP slowed tumor growth. By 1952, clinical trials commenced, involving 107 patients suffering from various cancers, including 45 children diagnosed with acute leukemia.

Before the advent of 6-MP, treatment options for these children were scarce, and prognosis was often grim. The results from the trials indicated that the children tolerated 6-MP well, with 15 of them achieving complete remission for periods ranging from a few weeks to several months. While this was not a long-term solution, it represented a significant improvement in treatment outcomes.

Elion’s emotional journey was marked by elation when the children improved and deep sorrow when they relapsed. This motivated her and Hitchings to pursue further research. In the late 1950s, they combined 6-MP with methotrexate, another chemotherapy drug developed by Dr. Jane Wright and her team, to enhance the duration of remission for children with acute leukemia.

Throughout her career, Elion continued to make remarkable contributions to medicine. She developed numerous drugs, including azathioprine, which is used for rheumatoid arthritis and transplant anti-rejection, as well as acyclovir, an antiviral for herpes, chickenpox, and shingles. Notably, she was also instrumental in creating AZT, the first effective treatment for HIV/AIDS.

In recognition of her groundbreaking work in drug design, Elion, together with Hitchings and James Black, received the Nobel Prize in Physiology or Medicine in 1988. Their collective efforts exemplified the principles of rational drug design and emphasized the importance of innovation in medical research.

Elion’s journey from being barred from research to becoming a Nobel laureate illustrates not only her personal tenacity but also the shifting landscape of women in science. Her work continues to inspire future generations of scientists and underscores the critical importance of diversity in research and innovation.